EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Combined PD-1 and CTLA-4 Blockade Increases the Risks of Multiple Pituitary Hormone Deficiency and Isolated Adrenocorticotropic Deficiency: A Prospective Study

Shintaro Iwama, Tomoko Kobayashi, Tetsushi Izuchi, Koji Suzuki, Takanori Murase, Masahiko Ando, Tomoko Handa, Takeshi Onoue, Takashi Miyata, Mariko Sugiyama, Daisuke Hagiwara, Hidetaka Suga und 8 weitere

Endocrinology and Metabolism · 2025

DOI: 10.3803/enm.2024.2180 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrinology and Metabolism, 2025. Verfasst von Shintaro Iwama und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan. Hauptthemen laut MEDLINE: Programmed Cell Death 1 Receptor, Adrenocorticotropic Hormone, CTLA-4 Antigen, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Anti-cytotoxic T-lymphocyte antigen-4 antibody (CTLA-4-Ab) monotherapy induces two types of pituitary immunerelated adverse events (irAEs): multiple pituitary hormone deficiency (Multi-D; impairment of ≥2 anterior pituitary hormones) and isolated adrenocorticotropic hormone (ACTH) deficiency (IAD). Combination therapy with CTLA-4-Ab and anti-programmed cell death-1 antibody (PD-1/CTLA-4-Abs), which is increasingly replacing CTLA-4-Ab monotherapy, frequently causes pituitary irAEs; however, whether it increases Multi-D/IAD incidence is unknown.

Methods

In total, 74 and 748 patients with malignancies treated with PD-1/CTLA-4-Abs and PD-1-Ab, respectively, were prospectively evaluated for ACTH and cortisol levels at baseline and every 6 weeks after treatment initiation, and then observed until the last clinical visit. The characteristics of pituitary irAEs were evaluated by pituitary stimulation tests and compared with those induced by PD-1-Ab monotherapy.

Results

PD-1/CTLA-4-Abs therapy showed higher incidence rates of pituitary irAEs (16/74 [21.6%] vs. 25/748 [3.3%], P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Programmed Cell Death 1 ReceptorAdrenocorticotropic HormoneCTLA-4 AntigenImmune Checkpoint InhibitorsHypopituitarismEndocrine System DiseasesNeoplasmsHumansMaleProspective StudiesFemaleMiddle AgedAdultAgedIncidenceFollow-Up StudiesDrug Therapy, CombinationPrognosisHypoglycemiaGenetic Diseases, Inborn

Stichwörter der Autor:innen

Adrenocorticotropic hormone deficiencyHypopituitarismImmune checkpoint inhibitorsImmunerelated adverse eventImmunotherapy

Substanzen

Programmed Cell Death 1 ReceptorAdrenocorticotropic HormoneCTLA-4 AntigenImmune Checkpoint InhibitorsPDCD1 protein, humanCTLA4 protein, human

Autor:innen und Institutionen

  • Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Center for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya, Japan.
  • Research Center of Health, Physical Fitness and Sports, Nagoya University, Nagoya, Japan.
  • Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Iwama, S., Kobayashi, T., Izuchi, T., Suzuki, K., Murase, T., Ando, M., Handa, T., Onoue, T., Miyata, T., Sugiyama, M., Hagiwara, D., Suga, H., Banno, R., Hase, T., Mori, S., Sano, T., Akamatsu, S., Akiyama, M., Ishii, M., & Arima, H. (2025). Combined PD-1 and CTLA-4 Blockade Increases the Risks of Multiple Pituitary Hormone Deficiency and Isolated Adrenocorticotropic Deficiency: A Prospective Study. Endocrinology and Metabolism. https://doi.org/10.3803/enm.2024.2180

Vancouver

Iwama S, Kobayashi T, Izuchi T, Suzuki K, Murase T, Ando M, et al. Combined PD-1 and CTLA-4 Blockade Increases the Risks of Multiple Pituitary Hormone Deficiency and Isolated Adrenocorticotropic Deficiency: A Prospective Study. Endocrinology and Metabolism. 2025. doi:10.3803/enm.2024.2180

BibTeX
@article{Iwama2025,
  author = {Iwama, Shintaro and Kobayashi, Tomoko and Izuchi, Tetsushi and Suzuki, Koji and Murase, Takanori and Ando, Masahiko and Handa, Tomoko and Onoue, Takeshi and Miyata, Takashi and Sugiyama, Mariko and Hagiwara, Daisuke and Suga, Hidetaka and Banno, Ryoichi and Hase, Tetsunari and Mori, Shoichiro and Sano, Tomoyasu and Akamatsu, Shusuke and Akiyama, Masashi and Ishii, Makoto and Arima, Hiroshi},
  title = {Combined PD-1 and CTLA-4 Blockade Increases the Risks of Multiple Pituitary Hormone Deficiency and Isolated Adrenocorticotropic Deficiency: A Prospective Study},
  journal = {Endocrinology and Metabolism},
  year = {2025},
  doi = {10.3803/enm.2024.2180}
}
Kostenlos starten →